Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Goss BD, Forman D, Ansell PE, Bennett V, Swerdlow AJ, Burge S, Ryan TJ
Januvia (Sitagliptin) Sales in 2022: $4.513 billion (includes sales of Janumet (sitagliptin + metformin)) Company/Developer: Merck Date of first FDA approval: October 16, 2006 Indications Januvia is FDA-approved for: Type 2 diabetes Price of Januvia: About $613 for a supply of 30 oral 100 mg tablets Why it did so well: Januvia is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated to improve glycemic control in patients with type 2 diabetes in conjunction with diet and exercise
The available research shows the following: A retrospective cohort study by Burke et al
[21] has been used in the semaglutide phase III development program, in which semaglutide showed a gastrointestinal AE profile comparable to that of other GLP-1 receptor agonists [23]
US$ 27.03
US$ 25.73
US$ 23.25
US$ 26.24
US$ 21.41
US$ 26.34
